These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 22124371)

  • 1. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.
    Khan O; La Thangue NB
    Immunol Cell Biol; 2012 Jan; 90(1):85-94. PubMed ID: 22124371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDAC inhibitor-based therapies and haematological malignancy.
    Stimson L; Wood V; Khan O; Fotheringham S; La Thangue NB
    Ann Oncol; 2009 Aug; 20(8):1293-302. PubMed ID: 19515748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.
    Khan O; La Thangue NB
    Nat Clin Pract Oncol; 2008 Dec; 5(12):714-26. PubMed ID: 18839006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC Inhibitors.
    Olzscha H; Bekheet ME; Sheikh S; La Thangue NB
    Methods Mol Biol; 2016; 1436():281-303. PubMed ID: 27246222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
    Duvic M; Dimopoulos M
    Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications.
    Thaler F
    Pharm Pat Anal; 2012 Mar; 1(1):75-90. PubMed ID: 24236715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy.
    Stengel KR; Hiebert SW
    Antioxid Redox Signal; 2015 Jul; 23(1):51-65. PubMed ID: 24730655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors: a review on class-I specific inhibition.
    Behera J; Jayaprakash V; Sinha BN
    Mini Rev Med Chem; 2015; 15(9):731-50. PubMed ID: 25994050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors: novel agents in cancer treatment.
    Glass E; Viale PH
    Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC inhibitors in cancer care.
    Tofilon PJ; Camphausen K
    Oncology (Williston Park); 2010 Feb; 24(2):180-5. PubMed ID: 20361469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
    Richon VM
    Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.
    Thurn KT; Thomas S; Moore A; Munster PN
    Future Oncol; 2011 Feb; 7(2):263-83. PubMed ID: 21345145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New and emerging HDAC inhibitors for cancer treatment.
    West AC; Johnstone RW
    J Clin Invest; 2014 Jan; 124(1):30-9. PubMed ID: 24382387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
    Chun P
    Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers for predicting clinical responses to HDAC inhibitors.
    Stimson L; La Thangue NB
    Cancer Lett; 2009 Aug; 280(2):177-83. PubMed ID: 19362413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC inhibitor-based therapies: can we interpret the code?
    New M; Olzscha H; La Thangue NB
    Mol Oncol; 2012 Dec; 6(6):637-56. PubMed ID: 23141799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
    Hymes KB
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):98-109. PubMed ID: 20371442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
    Zain J; O'Connor OA
    Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S58-78. PubMed ID: 21132350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
    Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
    Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecule of the month. Vorinostat.
    Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.